Literature DB >> 24005535

Platelet glycoprotein IIIA PIA1/A2 polymorphism in young patients with ST elevation myocardial infarction and idiopathic ischemic stroke.

Blanca Elsa Rivera-García1, Juan Carlos Esparza-García, Jose Luis Aceves-Chimal, Alfredo Leaños-Miranda, Abraham Majluf-Cruz, Irma Isordia-Salas.   

Abstract

It has been identified that platelet glycoprotein IIIa PIA1/A2 polymorphism plays an important role in atherothrombotic disease such as myocardial infarction and stroke, but results remain controversial. Here, we investigated whether the PIA2 allele is associated with ST myocardial infarction or idiopathic ischemic stroke in young individuals in two independent studies. In a case-control study 275 patients with ST elevation myocardial infarction ≤45 years of age and 278 controls were recruited. In a second study, 200 patients with idiopathic ischemic stroke ≤45 years of age and 200 controls were enrolled. In both studies cases and controls were matched by age and gender. The PIA1/A2 polymorphism was determined in all participants by a polymerase chain reaction-restriction fragment length polymorphism assay. There was a significant difference in the PIA1/A2 genotype distribution (P = 0.001) and allele frequency (P = 0.001), between ST elevation myocardial infarction and control groups, but not in the PIA1/A2 genotype distribution (P = 0.61) and allele frequency (P = 0.80), between idiopathic ischemic stroke. The allele PIA2 represented an independent risk for ST elevation myocardial infarction but not for idiopathic ischemic stroke. Hypertension, smoking, and family history of atherothrombotic disease were also associated with ST elevation myocardial infarction and idiopathic ischemic stroke. Our results suggest that PA2 allele represents a risk factor for ST elevation myocardial infarction in young Mexican individuals but not for idiopathic ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005535     DOI: 10.1007/s11010-013-1794-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  42 in total

1.  PIA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIIa and its correlation to cerebrovascular diseases: an appraisal.

Authors:  Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2007-12-26       Impact factor: 2.389

2.  Platelet glycoprotein IIIa PlA polymorphism in young men with myocardial infarction.

Authors:  A M Carter; N Ossei-Gerning; P J Grant
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

3.  Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death.

Authors:  R B Zotz; M Klein; H P Dauben; C Moser; E Gams; R E Scharf
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

4.  Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction.

Authors:  M M Zhu; J Weedon; L T Clark
Journal:  Am J Cardiol       Date:  2000-11-01       Impact factor: 2.778

5.  Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men.

Authors:  G Benze; J Heinrich; H Schulte; S Rust; U Nowak-Göttl; M-C Tataru; E Köhler; G Assmann; R Junker
Journal:  Eur Heart J       Date:  2002-02       Impact factor: 29.983

6.  PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke.

Authors:  Mary Lou P J van Goor; Encarna Gómez García; Geert-Jan Brouwers; Frank W G Leebeek; Peter J Koudstaal; Diederik W J Dippel
Journal:  Thromb Res       Date:  2002-10-01       Impact factor: 3.944

7.  Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke.

Authors:  Pasquale Madonna; Valentino de Stefano; Antonio Coppola; Ferdinando Cirillo; Anna Maria Cerbone; Giuseppe Orefice; Giovanni Di Minno
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

8.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

9.  The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction.

Authors:  E L Grove; T F Ørntoft; J F Lassen; H K Jensen; S D Kristensen
Journal:  J Intern Med       Date:  2004-06       Impact factor: 8.989

10.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.

Authors:  E J Weiss; P F Bray; M Tayback; S P Schulman; T S Kickler; L C Becker; J L Weiss; G Gerstenblith; P J Goldschmidt-Clermont
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

View more
  2 in total

1.  Interaction among CYP2C8, GPIIIa and P2Y12 variants increase susceptibility to ischemic stroke in Chinese population.

Authors:  Xingyang Yi; Jing Lin; Yanfen Wang; Ju Zhou; Qiang Zhou
Journal:  Oncotarget       Date:  2017-08-07

2.  Genetic Polymorphisms Associated with Thrombotic Disease Comparison of Two Territories: Myocardial Infarction and Ischemic Stroke.

Authors:  Irma Isordia-Salas; Manuel Martínez-Marino; Paolo Alberti-Minutti; María Tania Ricardo-Moreno; Ricardo Castro-Calvo; David Santiago-Germán; José Antonio Alvarado-Moreno; Cristian Calleja-Carreño; Jesús Hernández-Juárez; Alfredo Leaños-Miranda; Abraham Majluf-Cruz
Journal:  Dis Markers       Date:  2019-10-30       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.